Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 102.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 750,235 shares of the company's stock after buying an additional 379,828 shares during the quarter. Point72 Asset Management L.P. owned 2.27% of Lexeo Therapeutics worth $4,937,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Allostery Investments LP bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $33,000. China Universal Asset Management Co. Ltd. bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $46,000. Price T Rowe Associates Inc. MD bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $69,000. SG Americas Securities LLC bought a new position in Lexeo Therapeutics during the fourth quarter valued at about $72,000. Finally, Wells Fargo & Company MN boosted its stake in Lexeo Therapeutics by 49.9% during the fourth quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock valued at $73,000 after buying an additional 3,714 shares in the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Stock Up 1.5%

LXEO opened at $3.29 on Tuesday. Lexeo Therapeutics, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $19.50. The business has a 50-day moving average of $3.08 and a 200-day moving average of $4.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $109.22 million, a PE ratio of -1.04 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). Equities research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LXEO shares. Leerink Partners decreased their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research report on Monday, March 24th. HC Wainwright decreased their price target on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday. Chardan Capital decreased their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics has an average rating of "Buy" and an average price target of $20.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.